公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2019 | Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos | Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N; Kim D.-W; Tan D.S.W; CHIH-HSIN YANG ; Azrif M; Mitsudomi T; Park K; Soo R.A; Chang J.W.C; Alip A; Peters S; Douillard J.-Y. | Annals of Oncology | 209 | 174 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS | Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; CHIH-HSIN YANG ; Wang J.; Babu K.G.; Nakayama Y.; Alip A.; Chua K.L.M.; CHIA-HSIEN CHENG ; Senan S.; Ahn Y.C.; Kim T.-Y.; Ahn H.K.; Peters S.; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 67 | 58 | |
2023 | Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC | Kim, Hye Ryun; Awad, Mark M; Navarro, Alejandro; Gottfried, Maya; Peters, Solange; Csőszi, Tibor; Cheema, Parneet K; Rodriguez-Abreu, Delvys; Wollner, Mirjana; CHIH-HSIN YANG ; Mazieres, Julien; Orlandi, Francisco J; Luft, Alexander; Gümüş, Mahmut; Kato, Terufumi; Kalemkerian, Gregory P; Luo, Yiwen; Santorelli, Melissa L; Pietanza, M Catherine; Rudin, Charles M | JTO clinical and research reports | 0 | 0 | |
2022 | PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer | Woodford, Rachel; Zhou, Deborah; Lord, Sarah J; Marschner, Ian; Cooper, Wendy A; Lewis, Craig R; John, Thomas; CHIH-HSIN YANG ; Lee, Chee Khoon | Future oncology (London, England) | 8 | 6 | |
2018 | Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study | Gadgeel S.M; Stevenson J.P; Langer C.J; Gandhi L; Borghaei H; Patnaik A; Villaruz L.C; Gubens M; Hauke R; CHIH-HSIN YANG ; Sequist L.V; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V. | Lung Cancer | 69 | 60 | |
2019 | Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation | CHIH-HSIN YANG ; Gadgeel S.M; Sequist L.V; Wu C.-L; Papadimitrakopoulou V.A; Su W.-C; Fiore J; Saraf S; Raftopoulos H; Patnaik A. | Journal of Thoracic Oncology | 130 | 104 | |
2020 | Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 Study | Rudin C.M.; Awad M.M.; Navarro A.; Gottfried M.; Peters S.; Csoszi T.; Cheema P.K.; Rodriguez-Abreu D.; Wollner M.; CHIH-HSIN YANG ; Mazieres J.; Orlandi F.J.; Luft A.; G?m?? M.; Kato T.; Kalemkerian G.P.; Luo Y.; Ebiana V.; Pietanza M.C.; Kim H.R.; KEYNOTE-604 Investigators | Journal of Clinical Oncology | 389 | 303 | |
2023 | Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia | Cheng, Ying; CHIH-HSIN YANG ; Okamoto, Isamu; Zhang, Li; Hu, Jie; Wang, Donglin; Hu, Chengping; Zhou, Jianying; Wu, Lin; Cao, Lejie; Liu, Jiwei; Zhang, Helong; Sun, Hong; Wang, Ziping; Gao, Hongjun; Yan, Yan; Xiao, Suijun; Lin, Jianxin; Pietanza, M Catherine; Kurata, Takayasu | Immunotherapy | 1 | 1 | |
2024 | Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial | CHIH-HSIN YANG ; Han, Baohui; De La Mora Jiménez, Emmanuel; Lee, Jong-Seok; Koralewski, Piotr; Karadurmus, Nuri; Sugawara, Shunichi; Livi, Lorenzo; Basappa, Naveen S; Quantin, Xavier; Dudnik, Julia; Ortiz, Diego Moran; Mekhail, Tarek; Okpara, Chinyere E; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati; Csőszi, Tibor | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | | | |
2015 | Pemetrexed continuation maintenance in patients with nonsquamous non-small cell lung cancer: Review of two East Asian trials in reference to PARAMOUNT | CHIH-HSIN YANG ; Ahn M.-J; Nakagawa K; Tamura T; Barraclough H; Enatsu S; Cheng R; Orlando M. | Cancer Research and Treatment | 4 | 4 | |
2010 | Pemetrexed for heavily pretreated patients with advanced non-small cell lung cancer | JIH-HSIANG LEE ; CHONG-JEN YU ; KUAN-YU CHEN ; JIN-YUAN SHIH ; Lin Y.-L.; CHIH-HSIN YANG | Journal of the Formosan Medical Association | 6 | 5 | |
2014 | A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors | Ghamande S.; CHIA-CHI LIN ; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; CHIH-HSIN YANG ; ANN-LII CHENG ; Ghalib M.H.; Chuadhary I.; Goel S. | Investigational New Drugs | 23 | 15 | |
2011 | Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer | Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG ; Thertulien R; Wertheim M; Mazieres J; Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A. | Journal of Thoracic Oncology | 59 | 57 | |
2015 | Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients | Chang T.C.; Shiah H.S.; CHIH-HSIN YANG ; KUN-HUEI YEH ; ANN-LII CHENG ; Shen B.N.; Wang Y.W.; Yeh C.G.; Chiang N.J.; Chang J.Y.; Chen L.T. | Cancer Chemotherapy and Pharmacology | 87 | 74 | |
2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 39 | 36 | |
2021 | Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer | Yu H.A.; Paz-Ares L.G.; CHIH-HSIN YANG ; Lee K.H.; Garrido P.; Park K.; Kim J.-H.; Lee D.H.; Mao H.; Wijayawardana S.R.; Gao L.; Hozak R.R.; Chao B.H.; Planchard D. | Clinical Cancer Research | 34 | 30 | |
2019 | Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors | Doi T.; CHIH-HSIN YANG ; Shitara K.; Naito Y.; ANN-LII CHENG ; Sarashina A.; Pronk L.C.; Takeuchi Y.; CHIA-CHI LIN | Targeted Oncology | 21 | 14 | |
2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
2018 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer | Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG ; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. | Journal of Clinical Oncology | 245 | 211 | |
2004 | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | Lu Y.-S.; CHIUN HSU ; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIH-HUNG HSU ; Wu C.-Y.; ANN-LII CHENG | Hepato-Gastroenterology | 14 | 13 | |